A Conversation Between the Honorable NRC Commissioner David A. Wright and ACMUI Chair Hossein Jadvar [0.03%]
美国国立医学研究院委员DAVID A WRIGHT与ACMURIS主席HOSSAIN JADVAR对话
David A Wright,Hossein Jadvar
David A Wright
SPECT Versus PET for [177Lu]Lu-PSMA Response Assessment Using Quantitative RECIP 1.0 [0.03%]
定量RECIP 1.0评估[177Lu]Lu-PSMA反应:SPECT与PET的比较
Mutaz Kassas,Ayoub Jaafari,Qaid Ahmed Shagera et al.
Mutaz Kassas et al.
Prostate-specific membrane antigen (PSMA) PET/CT is widely used to monitor response during [177Lu]Lu-PSMA radiopharmaceutical therapy (RPT) in metastatic castration-resistant prostate cancer (mCRPC), but access and cost limit its routine us...
Is CXCR4 Theranostics in Oncologic, Cardiovascular, and Inflammatory Diseases Really Happening? [0.03%]
CXCR4在肿瘤、心血管和炎症性疾病中的治疗诊断真的可行吗？
Philipp E Hartrampf,Rudolf A Werner,Takahiro Higuchi et al.
Philipp E Hartrampf et al.
Single-Domain Antibody Probe with Low Renal Uptake for Claudin 18.2-Targeted PET Imaging of Gastric Cancer: Preclinical and Pilot Clinical Evaluations [0.03%]
一种用于Claudin 18.2靶向显像的低肾摄取单域抗体探针的PET成像：前期和首次临床评估
Meng Zheng,Haoqun Ma,Tao Xu et al.
Meng Zheng et al.
High renal uptake limits the clinical translation of Claudin 18.2 (CLDN18.2) nanobody probes. We aimed to develop and identify a single-domain antibody-based molecular probe to minimize nonspecific renal accumulation while maintaining high ...
Prognostic Value of Cycle 1 SPECT SUVmean in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 [0.03%]
镥-PSMA-617治疗转移性去势抵抗性前列腺癌患者时Cycle 1 SPECT SUVmean的预后价值
Alireza Ghodsi,Ridvan A Demirci,Roman Gulati et al.
Alireza Ghodsi et al.
This study aimed to determine whether SPECT SUVmean measured after the first cycle of 177Lu-PSMA-617 is associated with oncologic outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: This retrospective...
Actionable Feedback on Signal-to-Background Ratios During Drop-in Radioguided Surgery [0.03%]
基于信号与背景比率的可操作反馈在微创术中放射导航手术中的应用
Berkay A Cakal,Kateryna Pirkovets,Vera A Ottens et al.
Berkay A Cakal et al.
Radioguided surgery (RGS) using prostate-specific membrane antigen (PSMA)-targeted tracers is frequently hampered by relatively low intraoperative signal intensities. This limits intraoperative target discrimination when feedback relies sol...
Assessment of CCR2 PET as a Biomarker for Head and Neck Squamous Cell Carcinoma [0.03%]
CCR2 PET在头颈鳞癌中生物标志物价值的评估研究
Alexandria Li,Deborah Sultan,Gyu Seong Heo et al.
Alexandria Li et al.
Because of the lack of prognostic biomarkers, most patients with head and neck squamous cell carcinoma (HNSCC) are diagnosed at an advanced stage of the disease, leading to poor overall survival. There is an unmet need to identify biomarker...
PD-L1 Immuno-PET Reveals Systemic Effects of Localized Oncolytic Virotherapy in a Mouse Model of Head and Neck Cancer [0.03%]
局部溶瘤病毒治疗在头颈癌小鼠模型中对全身免疫的影响及机理研究被PD-L1免疫-PET显像揭示
Julia Höbart,Chiara Da Pieve,Florian Raes et al.
Julia Höbart et al.
Immune checkpoint inhibitors can trigger antitumor immunity, yet most patients, including those with head and neck cancer, show limited benefit because of insufficient immune activation at the tumor site. Oncolytic virotherapy (OV) may over...
Remco J Poelarends,Jorn A van Dalen,Riemer H J A Slart et al.
Remco J Poelarends et al.
Prostate-Specific Membrane Antigen Radioligand Therapy in Patients with Aggressive-Variant Prostate Cancer [0.03%]
前列腺特异性膜抗原放射配体治疗伴发侵袭性变异型前列腺癌患者的疗效分析
Moein Moradpour,Abuzar Moradi Tuchayi,Surekha Yadav et al.
Moein Moradpour et al.
Aggressive-variant prostate cancer (AVPC) is characterized by several high-risk features and is typically treated with chemotherapy. In this study, we evaluated the outcomes of patients with AVPC who received prostate-specific membrane anti...